Corbus Pharma Q3 net loss $8.8M ($0.07/shr); cash $67M; CRB-601 IND on track for mid-2023

Corbus Pharmaceuticals Holdings, Inc.

Net loss of $8.8M ($0.07 per share) vs $2.2M loss in Q3 2021; prior year included $12.3M tax credit.
Operating expenses decreased to $8.2M from $14.0M, driven by lower clinical trial and manufacturing costs.
Cash and investments $67M; amended debt agreement defers principal payments to September 2023, extending runway.
CRB-601 pre-clinical data at SITC; IND submission on track for mid-2023.
Actively exploring partnerships for CRB-913 (CB1 inverse agonist) for obesity.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Corbus Pharmaceuticals Holdings, Inc. reported the three months ended September 30, 2022 results: net income net loss of approximately $8.8 million, EPS net loss per diluted share of $0.07.

Period: the three months ended September 30, 2022
Net income: net loss of approximately $8.8 million
EPS: net loss per diluted share of $0.07
Result: reported results

Exact text from the filing

The Company reported a net loss of approximately $8.8 million, or a net loss per diluted share of $0.07, for the three months ended September 30, 2022

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Corbus Pharmaceuticals Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-026872

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.